Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TVRD Tvardi Therapeutics Inc

未开盘 07-31 16:00:00 EDT

2.10

+0.00

0.00%

盘后2.10

+0.000.00%

19:35 EDT

最高2.13	最低2.00	成交量18.54万
今开2.08	昨收2.10	日振幅6.19%
总市值1,970万	流通市值1,191万	总股本938.13万
成交额38.42万	换手率3.27%	流通股本567.13万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":2.1,"timestamp":1785528000000,"preClose":2.1,"halted":0,"volume":185429,"hourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.1,"latestTime":"19:35 EDT","volume":20,"amount":42.34,"timestamp":1785540939688,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":5671300,"shares":9381344,"eps":-2.482384,"marketStatus":"未开盘","change":0,"latestTime":"07-31 16:00:00 EDT","open":2.08,"high":2.13,"low":2,"amount":384221.79385839996,"amplitude":0.061905,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.482384,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":0,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":2.1,"preHourTrading":{"tag":"盘前","latestPrice":2.13,"preClose":2.1,"latestTime":"09:28 EDT","volume":321,"amount":683.6242626,"timestamp":1785504525523,"change":0.03,"changeRate":0.014286,"amplitude":0.00219},"postHourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.1,"latestTime":"19:35 EDT","volume":20,"amount":42.34,"timestamp":1785540939688,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.2716066345011045,"impliedVol":0.4194,"impliedVolPercentile":0.125},"requestUrl":"/m/hq/s/TVRD/wiki","defaultTab":"wiki","newsList":[{"id":"1182444367","title":"Piper Sandler将Tvardi Therapeutics评级上调至“增持”，目标价大幅提升至13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182444367","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182444367?lang=zh_cn&edition=full","pubTime":"2026-07-09 12:01","pubTimestamp":1783569678,"startTime":"0","endTime":"0","summary":"Piper Sandler发布最新研究报告，将生物制药公司Tvardi Therapeutics Inc的股票评级从“中性”显著上调至“增持”。与此同时，该机构大幅提高了其目标价，从此前的3美元跃升至13美元，显示出对公司未来发展前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157277204","title":"Tvardi Therapeutics旗下Tti-109展现快速转化与高达60%的Stat3驱动免疫细胞减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1157277204","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157277204?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:05","pubTimestamp":1783422349,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics公司宣布，其候选药物Tti-109在临床前研究中表现出快速转化能力，并能够将Stat3驱动的免疫细胞数量减少高达60%。这一数据凸显了该药物在调节关键免疫信号通路方面的潜在效力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121974132","title":"Tvardi Therapeutics Tti-109 I期研究证实前药设计、耐受性改善及Stat3靶点参与的药效学证据","url":"https://stock-news.laohu8.com/highlight/detail?id=1121974132","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121974132?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:05","pubTimestamp":1783422322,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics公司近日公布了其候选药物Tti-109的I期临床研究数据。该数据有力地证实了其前体药物设计的合理性，同时显示出良好的耐受性改善，并提供了Stat3靶点参与的药效学证据。此外，在患者样本中观察到的药效学变化，为Stat3这一关键信号通路被有效抑制提供了直接证据。Stat3蛋白在多种肿瘤的发生与发展中扮演着核心角色，是肿瘤治疗领域备受关注的热门靶点。此次I期研究的积极结果，为Tti-109后续的临床开发奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121049283","title":"Tvardi Therapeutics 计划推进Tti-109用于STAT3驱动皮肤病及胃肠道疾病——需额外资金支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1121049283","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121049283?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:04","pubTimestamp":1783422284,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc 宣布，计划将其候选药物Tti-109的开发重点，拓展至由STAT3信号通路驱动的皮肤病和胃肠道疾病领域。然而，这一战略推进的实施，将取决于公司能否成功获得必要的额外资金。Tti-109旨在靶向并抑制STAT3的活性，从而可能为这些难治性疾病提供新的治疗选择。公司表示，新的开发计划将基于Tti-109已有的临床前数据及其作用机制的科学依据。此举标志着Tvardi在探索其核心资产Tti-109治疗潜力方面，迈出了战略性的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165971805","title":"Tvardi Therapeutics Inc：现金储备预计足以支撑运营至临床数据公布期及2026年第四季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1165971805","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165971805?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:10","pubTimestamp":1778238631,"startTime":"0","endTime":"0","summary":"生物制药公司Tvardi Therapeutics Inc近日宣布，其现有资金储备预计可充分支持公司运营至关键临床试验数据公布阶段，并持续维持至2026年第四季度。这一财务规划为公司在肿瘤治疗领域核心药物的临床开发提供了稳定保障。随着临床研究进入关键阶段，投资者可重点关注该公司在实体瘤和血液恶性肿瘤治疗领域的数据更新。稳定的现金储备为Tvardi Therapeutics在竞争激烈的生物科技赛道中提供了独特的续航优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178271385","title":"Tvardi Therapeutics Inc将于2026年6月公布Tti-109关键数据及临床开发战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1178271385","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178271385?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:10","pubTimestamp":1778238625,"startTime":"0","endTime":"0","summary":"生物制药公司Tvardi Therapeutics Inc近日透露，其核心候选药物Tti-109的关键临床试验数据以及后续临床开发战略，预计将在2026年6月正式对外公布。\n此次即将披露的顶线数据备受业界关注，其结果将直接影响该药物未来的研发路径与商业化前景。公司计划基于这些数据制定明确的临床推进策略，为后续研究阶段提供清晰方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://tvarditherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1633},{"period":"1month","weight":0.0769},{"period":"3month","weight":-0.3312},{"period":"6month","weight":-0.471},{"period":"1year","weight":-0.9191},{"period":"ytd","weight":-0.5116}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tvardi Therapeutics, Inc.于2017年12月20日注册成立，是一家总部位于德克萨斯州休斯顿的特拉华州公司。该公司是一家临床阶段的生物制药公司，专注于开发针对STAT3的新型口服小分子疗法，以治疗具有重大未满足需求的纤维化驱动疾病。基于其创始人的开创性工作和对转录因子STAT3的深刻理解，该公司设计了一种创新方法来直接抑制STAT3，这是一种经过高度验证但在历史上是不可药物的靶点。利用这些专业知识，该公司正在开发具有差异化作用机制和方便的口服给药的STAT3抑制剂管道。该公司的主要候选产品TTI-101目前处于2期临床开发阶段，用于治疗纤维化驱动的疾病，初步重点是特发性肺纤维化、IPF和肝细胞癌、HCC。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.032141},{"month":2,"riseRate":0.384615,"avgChangeRate":0.018638},{"month":3,"riseRate":0.538462,"avgChangeRate":0.004527},{"month":4,"riseRate":0.230769,"avgChangeRate":-0.045527},{"month":5,"riseRate":0.615385,"avgChangeRate":0.014602},{"month":6,"riseRate":0.538462,"avgChangeRate":-0.049775},{"month":7,"riseRate":0.538462,"avgChangeRate":0.092257},{"month":8,"riseRate":0.5,"avgChangeRate":0.010865},{"month":9,"riseRate":0.25,"avgChangeRate":-0.036951},{"month":10,"riseRate":0.5,"avgChangeRate":-0.10272},{"month":11,"riseRate":0.5,"avgChangeRate":0.037928},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016361}],"exchange":"NASDAQ","name":"Tvardi Therapeutics Inc","nameEN":"Tvardi Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tvardi Therapeutics Inc,TVRD,Tvardi Therapeutics Inc股票,Tvardi Therapeutics Inc股票老虎,Tvardi Therapeutics Inc股票老虎国际,Tvardi Therapeutics Inc行情,Tvardi Therapeutics Inc股票行情,Tvardi Therapeutics Inc股价,Tvardi Therapeutics Inc股市,Tvardi Therapeutics Inc股票价格,Tvardi Therapeutics Inc股票交易,Tvardi Therapeutics Inc股票购买,Tvardi Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}